AngioDynamics Announces FDA 510(k) Clearance Of Auryon XL Radial Access Catheter To Treat Peripheral Arterial Disease
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics, Inc. (NASDAQ:ANGO) has received FDA 510(k) clearance for its Auryon XL Catheter, designed for radial access in treating Peripheral Arterial Disease (PAD). The Auryon XL Catheter aims to reduce access site complications and improve patient recovery times. It is compatible with the Auryon Atherectomy System, which has been used to treat over 50,000 patients in the U.S. The company began a limited market release in January 2024 and plans a full market release in February 2024.
January 23, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AngioDynamics' Auryon XL Catheter has received FDA clearance, indicating a positive development for the company's product line and potential for increased market share in PAD treatment.
The FDA clearance is a significant regulatory milestone that typically leads to increased product credibility and market adoption. The Auryon XL Catheter's benefits, such as reduced complications and faster recovery, are likely to be well-received by healthcare providers and patients, potentially leading to increased sales and positive stock price movement in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100